GLP-1 Weight Loss in New Jersey: What Patients Should Understand
Published by New Jersey Trim Clinic · Updated 2026-05-03
What Is GLP-1 and Why Does It Matter for Weight Loss?
GLP-1 — glucagon-like peptide-1 — is a hormone your body produces naturally after eating. It signals to your brain that you are full, slows digestion, and reduces appetite. GLP-1 receptor agonist medications mimic this hormone, amplifying its effects to produce significant, sustained appetite suppression.
The clinical results are among the strongest ever recorded for non-surgical weight loss. Semaglutide (Ozempic, Wegovy) produces average weight loss of 15–17% of body weight. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP receptors, often producing even stronger results — 20–22% body weight reduction in clinical trials.
What Patients in New Jersey Should Know
Food noise disappears. The most commonly reported experience among GLP-1 patients is the near-complete elimination of food noise — the constant mental preoccupation with food, cravings, and eating that drives overconsumption. Patients describe it as "the thoughts just stopped."
Weight loss is gradual and sustainable. Unlike crash diets, GLP-1 medications work over months, not days. Most patients see meaningful changes within 4–8 weeks and continue losing for 12–18+ months.
Side effects are manageable. Mild nausea during dose escalation is the most common side effect. Most patients experience this for a week or two, then it resolves. Physician supervision helps manage this appropriately.
Telehealth makes it accessible. For NJ residents, accessing GLP-1 programs no longer means driving to a clinic. Telehealth programs like New Jersey Trim Clinic deliver physician-supervised care and medication directly to your home.
Starting GLP-1 Therapy in New Jersey
New Jersey Trim Clinic offers GLP-1 programs from $149/mo all-inclusive — semaglutide $149/mo, tirzepatide $169/mo, physician-supervised, all 21 NJ counties, FDA-registered American pharmacies.
👉 Get Started Today · Check If You Qualify
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- NIH/NIDDK — Factors Affecting Weight & Health
Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.
Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supports: FDA identifies potential safety risks and limited human safety information for certain substances proposed for compounding, including some peptides.
Evidence limits: This safety source does not substantiate claims that unapproved peptide treatments improve cognition, muscle, tissue repair, recovery or longevity.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.